← Human Trials & Peer-Reviewed Studies
Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies
Plain-language guide to PMID 31221697 (2019): randomized controlled trial study of Exenatide and Liraglutide in 35 people.
Key Facts
- PMID
- 31221697
- Journal
- Diabetes care
- Year
- 2019
- Study type
- Randomized Controlled Trial
- Authors
- Zhang Z et al. (9 authors)
- DOI
- 10.2337/dc18-2584
- Registered trial
- NCT05313529
What This Study Did, in Plain Language
What Was Tested
Researchers studied Exenatide and Liraglutide in this randomized controlled trial publication.
Large numbers of people with type 2 diabetes are obese.
However, changes in cognition and related brain function in obese people with diabetes have not been characterized.
Here, the researchers investigated cognition, olfactory function, and odor-induced brain alterations in these patients and therapeutic effects of glucagon-like peptide 1 receptor agonists (GLP-1Ras) on their psychological behavior and olfactory networks.
Who Took Part
According to the abstract, 35 people were involved.
By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.
Cognitive, olfactory, and odor-induced brain activation assessments were administered to 35 obese and 35 nonobese people with type 2 diabetes and 35 control subjects matched for age, sex, and education.
Among them, 20 obese individuals with diabetes with inadequate glycemic control and metformin monotherapy received GLP-1Ra treatment for 3 months and were reassessed for metabolic, cognitive, olfactory, and neuroimaging changes.
How the Study Was Run
The researchers set it up as a randomized study.
The people were allocated by chance, so the Exenatide group and the comparison group should start out alike.
A time span of 3 months appears in the methods.
What Was Measured
The subject headings attached to it are Adiposity, Blood Glucose, Brain, Cognition, Cognitive Dysfunction, Diabetes Mellitus, Type 2 and Exenatide.
What This Means in Plain Language
The paper is a randomized study of Exenatide and Liraglutide in 35 people over 3 months.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2019 (Diabetes care), a journal based in United States.
More context: the Exenatide compound page and the Liraglutide compound page.
Our Notes on the Compounds
Exenatide: A 39-amino-acid GLP-1 receptor agonist first identified in Gila monster venom; sold as Byetta and Bydureon for type 2 diabetes.
Liraglutide: A once-daily GLP-1 receptor agonist peptide; sold as Victoza for type 2 diabetes and Saxenda for weight management.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.